What is Harvard Bioscience?
Harvard Bioscience, Inc. is a prominent developer, manufacturer, and seller of advanced technologies, products, and services essential for fundamental breakthroughs in life science applications. These applications span critical fields including academic and pharmaceutical research, therapy discovery, bio-production, and preclinical testing for drug development. The company serves a diverse customer base, from esteemed academic institutions and government laboratories to leading global pharmaceutical, biotechnology, and contract research organizations. With a strategic international presence across the United States, Europe, and China, Harvard Bioscience effectively reaches customers worldwide through a combination of direct sales and distribution networks.
How much funding has Harvard Bioscience raised?
Harvard Bioscience has raised a total of $156.4M across 3 funding rounds:
Stock Offering
$51.4M
Debt
$65M
Debt
$40M
Stock Issuance/Offering (2000): $51.4M, investors not publicly disclosed
Debt (2020): $65M led by Citizens Bank
Debt (2025): $40M supported by BroadOak Capital Partners
Key Investors in Harvard Bioscience
Citizens Bank
Citizens Bank, a major financial institution, has provided debt financing to Harvard Bioscience. Their involvement suggests a focus on supporting established companies with robust financial structures and growth potential.
BroadOak Capital Partners
BroadOak Capital Partners is a boutique financial institution specializing in direct investment and banking services for life sciences and biopharma services companies. Their participation indicates a strategic alignment with Harvard Bioscience's mission in the life sciences sector.
What's next for Harvard Bioscience?
The recent strategic investment in Harvard Bioscience signals a pivotal phase for the company, likely aimed at accelerating product development, expanding market reach, and enhancing its technological capabilities. Given the enterprise-level nature of its total capital raised, the company appears poised for significant growth and further integration into the pharmaceutical and biotechnology value chain. Future initiatives may focus on leveraging its comprehensive suite of tools for drug discovery and preclinical testing, potentially through strategic partnerships or acquisitions, to solidify its leadership in enabling fundamental advances in life science.
See full Harvard Bioscience company page
